期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 11, 期 8, 页码 593-599出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2005.04.005
关键词
reduced-intensity allogeneic stem cell transplantation; non-Hodgkin lymphoma; chemotherapy sensitivity; prognosis
Chemotherapy sensitivity has been identified as an important prognostic factor in reduced-intensity allogeneic stem cell transplantation (RIST) for non-Hodgkin lymphoma (NHL). However, the effect of uniform salvage chemotherapy before KIST has not been studied prospectively. We examined whether the response to prospectively administered uniform salvage therapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and fludarabine) influenced the subsequent outcome of KIST in 28 patients with relapsed or refractory NHL. After RIST, overall survival (OS) at 36 months is 49%, whereas event-free survival (EFS) is 32%. In Cox model analyses, the response to chemotherapy was the best predictor of OS (P =.0006) and EFS (P =.0006) after KIST. Differentiating stable disease from progressive disease after salvage chemotherapy strengthened the association with survival. Among chemotherapy-sensitive patients, the median OS and EFS have not been reached. In patients with stable disease, OS and EFS at 24 months are 50% and 25%, respectively. In contrast, only 1 patient with progressive disease during salvage therapy survived longer than 12 months. These prospective data confirm the favorable prognosis for chemotherapy-sensitive NHL after KIST and suggest that chemotherapy resistance is not an absolute contraindication to KIST for NHL patients with stable disease during salvage therapy. (c) 2005 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据